Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm

Table 1 Baseline characteristics of the TACE/TAE+ SBRT and SBRT groups

	TACE/TAE + SBRT (n = 77)	SBRT (n = 50)	P value
Age ≥60/<60 years	60/17	39/11	0.992
Gender (male/female)	67/10	45/5	0.610
HBsAg (unknown/negative/positive)	0/4/73	2/4/44	0.456
CTP class (A/B)	70/7	41/9	0.139
ECOG (0/1)	60/17	39/11	0.545
Nodules (solitary/multiple)	50/27	37/13	0.283
Recurrent/Primary	10/67	5/45	0.324
BCLC (A/B)	50/27	37/13	0.283
Liver cirrhosis (Yes/No)	57/20	38/12	0.485
AFP ≥100 ng/mL (Yes/No)	44/33	30/20	0.562
Tumor size (5–10 cm/≥10 cm)	51/26	43/7	0.013*
EQD₂ (≥/<74Gy)	49/28	43/7	0.150
BED₁₀ (≥/<100Gy)	24/53	21/29	0.031*
30-45Gy/3Fr;38-48Gy/4Fr;35-50Gy/5Fr	43/23/11	31/15/4	0.695

AFP alpha fetoprotein, BED biologically effective dose, BCLC Barcelona clinic liver cancer, CTP Child–Turcotte–Pugh, EQD₂ equivalent dose in 2Gy fraction, ECOG Eastern cooperative oncology group, Fr fractions, SBRT stereotactic body radiation therapy, TACE/TAE trans-arterial embolization; *P < 0.05

ISSN: 1471-2407